Free Trial
LON:SHP

Shire (SHP) Share Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
51,588 shs
Average Volume
3.14 million shs
Market Capitalization
£42.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SHP stock logo

About Shire Stock (LON:SHP)

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

SHP Stock News Headlines

South Harz Potash Ltd SHP
Jeff Bezos Next Trillion Dollar Bet
While the world has been obsessed with AI and ChatGPT… Jeff Bezos has quietly gone all in on a technology that's going to prove to be FAR bigger. If you've never heard of "QaaS" technology you need watch this.
Jeff Bezos Next Trillion Dollar Bet
While the world has been obsessed with AI and ChatGPT… Jeff Bezos has quietly gone all in on a technology that's going to prove to be FAR bigger. If you've never heard of "QaaS" technology you need watch this.
See More Headlines
Receive SHP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
£42.73 billion
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Flemming Ornskov M.P.H. (Age 60)
    MBA, M.D., MPH, CEO, MD & Exec. Director
  • Mr. Thomas J. W. Dittrich (Age 54)
    CFO & Director
  • Gisele Dion
    Chief Accounting Officer
  • Mr. Matthew Walker (Age 54)
    Head of Technical Operations
  • Dr. Andreas Busch Ph.D. (Age 55)
    Head of R&D and Chief Scientific Officer

Should I Buy Shire Stock? SHP Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Shire plc:

  • Shire plc is a biotechnology company that researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide.
  • Recent developments in the company's therapeutic areas, including hematology, genetic diseases, and neuroscience, show promising advancements in treatment options.
  • Shire plc has a strong track record of innovation and bringing new products to market, which can lead to potential revenue growth.
  • The company's focus on rare diseases and specialized conditions provides a niche market opportunity with potentially less competition.
  • Current stock price of Shire plc is stable and has shown positive growth trends in recent periods, indicating a potential for good returns on investment.

Cons

Investors should be bearish about investing in Shire plc for these reasons:

  • Shire plc operates in the highly regulated biotechnology and pharmaceutical industry, which can pose challenges in terms of compliance and market approvals.
  • Market volatility and changes in healthcare policies can impact the company's revenue streams and profitability.
  • Competition from other biotech companies and potential disruptions in supply chains could affect Shire plc's market position.
  • Investing in biotechnology companies carries inherent risks related to clinical trial outcomes, regulatory approvals, and patent protections.
  • While the company has shown growth potential, investors should carefully consider the risks associated with investing in a specialized sector like rare diseases and biotechnology.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, July 5, 2024. Please send any questions or comments about these Shire pros and cons to contact@marketbeat.com.

SHP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shire investors own include Barclays (BARC), Centrica (CNA), Erie Indemnity (ERIE), Lloyds Banking Group (LLOY), GSK (GSK), International Consolidated Airlines Group (IAG) and Vodafone Group Public (VOD).

This page (LON:SHP) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners